Literature DB >> 7955603

Serum uric acid levels and gout: what does this herald for the population?

A S Rigby1, P H Wood.   

Abstract

OBJECTIVE: To compare the Rome and New York criteria for gout.
METHODS: The Rome and New York criteria were compared in 59 patients with gout and in 761 with non-gout by calculating statistical indices such as sensitivity, specificity, relative value (sensitivity + specificity) and the log-likelihood ratio.
RESULTS: The best individual criterion was one or more attacks of podagra (New York version) which had a relative value of 194. In contrast, the presence of a tophus was the least valuable criterion with a discriminatory value which was less than three times the most valuable (podagra). The rarity with which either response to Colchicine therapy or measurement for urate crystals were sought makes them poor criteria. Serum uric acid (SUA) followed an approximate Normal Distribution in both sexes, although there were some interesting differences across age strata. In males, SUA showed a progressive rise with age interrupted by a hiccup in the mid-40s. In females, SUA fell slowly as menstruation started, followed by a gradual postmenopausal rise. The mean SUA in males was 294 mumol/l (95% CI = 278-330 mumol/l) and in females 230 mumol/l (95% CI = 224-236 mumol/l).
CONCLUSION: Despite higher levels of SUA in gouty patients, there was no lower level of SUA from which gout was not diagnosed, which vindicates its removal from the New York criteria set.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955603

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

Review 1.  New classification criteria for gout: a framework for progress.

Authors:  Nicola Dalbeth; Jaap Fransen; Tim L Jansen; Tuhina Neogi; H Ralph Schumacher; William J Taylor
Journal:  Rheumatology (Oxford)       Date:  2013-04-22       Impact factor: 7.580

2.  Gout is on the increase in New Zealand.

Authors:  P Klemp; S A Stansfield; B Castle; M C Robertson
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

Review 3.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; E Pascual; T Bardin; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

4.  A Point-of-Care Raman Spectroscopy-Based Device for the Diagnosis of Gout and Pseudogout: Comparison With the Clinical Standard Microscopy.

Authors:  Bolan Li; Nora G Singer; Yener N Yeni; Donard G Haggins; Emma Barnboym; Daniel Oravec; Steven Lewis; Ozan Akkus
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

5.  Performance of the Existing Classification Criteria for Gout in Thai Patients Presenting With Acute Arthritis.

Authors:  Kanon Jatuworapruk; Panomkorn Lhakum; Nuttaya Pattamapaspong; Nuntana Kasitanon; Suparaporn Wangkaew; Worawit Louthrenoo
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

6.  Dual-energy computed tomography has limited diagnostic sensitivity for short-term gout.

Authors:  Ertao Jia; Junqing Zhu; Wenhui Huang; Xiaoguang Chen; Juan Li
Journal:  Clin Rheumatol       Date:  2017-08-12       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.